Phase III RCT in 445 adults with moderate-to-severe grass-pollen allergic rhinoconjunctivitis: 26 months of 5-grass-pollen SLIT drops versus placebo improved the combined symptom and medication score in the second peak season (difference 1.88; relative 26.51%).
RCTn = 445
Didier et al. Five-Grass-Pollen Sublingual Immunotherapy Drops Are Efficacious and Well Tolerated in Adults: The RHAPSODY Phase III Trial